125 related articles for article (PubMed ID: 30943029)
21. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors.
Kim DC; Lee YR; Yang BS; Shin KJ; Kim DJ; Chung BY; Yoo KH
Eur J Med Chem; 2003 May; 38(5):525-32. PubMed ID: 12767603
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
24. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
[TBL] [Abstract][Full Text] [Related]
25. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
26. Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
Jorda R; Schütznerová E; Cankař P; Brychtová V; Navrátilová J; Kryštof V
Bioorg Med Chem; 2015 May; 23(9):1975-81. PubMed ID: 25835357
[TBL] [Abstract][Full Text] [Related]
27. Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.
Moravcová D; Krystof V; Havlícek L; Moravec J; Lenobel R; Strnad M
Bioorg Med Chem Lett; 2003 Sep; 13(18):2989-92. PubMed ID: 12941318
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Baek D; Choi J; Lee H; Oh CH
J Enzyme Inhib Med Chem; 2016; 31(sup2):111-122. PubMed ID: 27255180
[TBL] [Abstract][Full Text] [Related]
29. Novel pyrazolopyrimidines: Synthesis, in vitro cytotoxic activity and mechanistic investigation.
Hassan GS; Abdel Rahman DE; Nissan YM; Abdelmajeed EA; Abdelghany TM
Eur J Med Chem; 2017 Sep; 138():565-576. PubMed ID: 28704759
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
[TBL] [Abstract][Full Text] [Related]
31. Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.
Jarry M; Lecointre C; Malleval C; Desrues L; Schouft MT; Lejoncour V; Liger F; Lyvinec G; Joseph B; Loaëc N; Meijer L; Honnorat J; Gandolfo P; Castel H
Neuro Oncol; 2014 Nov; 16(11):1484-98. PubMed ID: 24891448
[TBL] [Abstract][Full Text] [Related]
32. RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.
Lamie PF
Bioorg Med Chem Lett; 2016 Jul; 26(13):3093-3097. PubMed ID: 27189674
[TBL] [Abstract][Full Text] [Related]
33. Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.
Wang X; Berger DM; Salaski EJ; Torres N; Dutia M; Hanna C; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E; Lucas J
J Med Chem; 2010 Nov; 53(21):7874-8. PubMed ID: 20961062
[TBL] [Abstract][Full Text] [Related]
34. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.
Trova MP; Barnes KD; Barford C; Benanti T; Bielaska M; Burry L; Lehman JM; Murphy C; O'Grady H; Peace D; Salamone S; Smith J; Snider P; Toporowski J; Tregay S; Wilson A; Wyle M; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6608-12. PubMed ID: 19846305
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
36. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
[TBL] [Abstract][Full Text] [Related]
37. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
38. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.
Lücking U; Siemeister G; Schäfer M; Briem H; Krüger M; Lienau P; Jautelat R
ChemMedChem; 2007 Jan; 2(1):63-77. PubMed ID: 17131463
[TBL] [Abstract][Full Text] [Related]
39. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
[TBL] [Abstract][Full Text] [Related]
40. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
